Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $12.73
Key levels
Resistance$11.74
Resistance$10.88
Support$9.88
Support$8.94
Latest news & SEC filings
ProductMonte Rosa Therapeutics shares early MRT-8102 study results at ACR Convergence 2026
AnalystWells Fargo trims Monte Rosa Therapeutics price target, keeps bullish call
AnalystWells Fargo keeps Overweight rating on Monte Rosa Therapeutics, cuts target to $25
All GLUE news →Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops molecular glue degraders, small molecules designed to eliminate disease-causing proteins. Its pipeline includes product candidates targeting GSPT1, VAV1, NEK7, CDK2, and CCNE1, with lead programs in oncology and immunology. The company uses its proprietary QuEEN discovery engine to identify and design these degraders. It operates in the United States and has collaborations with Novartis and Roche.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
SEPT Low Target
$25.00
SEPT Mid Target
$27.00
SEPT High Target
$28.00
Analyst Consensus
$27.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GLUE.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$23.38
9
Moat Score
NONE
5/9
Piotroski Score
1.7
Altman Z-Score
Insider Signal
SELLING
0 buys / 14 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bowen Matthew | officer | Sale | 13 | $137.28 | Oct 5, 2026 |
| Warmuth Markus | director officer | Sale | 4,998 | $97K | Jun 1, 2026 |
| Warmuth Markus | director officer | Sale | 468 | $9K | Jun 1, 2026 |
| Townson Sharon | officer | Buy | 6,000 | $37K | May 29, 2026 |
| Townson Sharon | officer | Sale | 6,000 | $119K | May 29, 2026 |
| Champoux Jennifer | officer | Buy | 2,175 | $9K | May 27, 2026 |
| Champoux Jennifer | officer | Sale | 2,175 | $44K | May 27, 2026 |
| Champoux Jennifer | officer | Buy | 2,176 | $9K | May 22, 2026 |
| Champoux Jennifer | officer | Sale | 2,176 | $41K | May 22, 2026 |
| Manning Anthony M. | director | Buy | 10,000 | $42K | May 21, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
63.5%
3yr Revenue CAGR
N/A%
EPS Growth YoY
53.06%
FCF Growth YoY
-172.3%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for GLUE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:45 | $10.31 | 6,016 | $$62K | SELL |
| 21:00:16 | $10.31 | 1,434 | $$15K | SELL |
| 21:00:16 | $10.31 | 4,065 | $$42K | SELL |
| 21:00:16 | $10.31 | 1,688 | $$17K | SELL |
| 21:00:16 | $10.31 | 4,040 | $$42K | SELL |
5 dark pool trades shown · $$178K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Monte Rosa Therapeutics, Inc. (GLUE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Monte Rosa Therapeutics, Inc. (GLUE) is at $10.09, down 2.13% (-$0.22) at the Nov 12, 2026 close.
Latest GLUE news — Nov 9, 2026: Monte Rosa Therapeutics shares early MRT-8102 study results at ACR Convergence 2026 · Nov 7, 2026: Wells Fargo trims Monte Rosa Therapeutics price target, keeps bullish call
The average analyst price target for GLUE is $27.00, ranging from $25 to $28, based on 6 analysts.
Analyst ratings for GLUE: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
GLUE last reported on Aug 6, 2026: EPS -$0.43 vs -$0.38 expected — a miss of 13.0%.
GLUE does not currently pay a dividend.
Support: $9.88, $8.94, $7.87. Resistance: $10.88, $11.74, $12.73.
Insider activity: SELLING, 0 buys and 14 sells in the last 90 days.
Nov 9, 2026: Monte Rosa Therapeutics shares early MRT-8102 study results at ACR Convergence 2026 · Nov 7, 2026: Wells Fargo trims Monte Rosa Therapeutics price target, keeps bullish call · Nov 6, 2026: Wells Fargo keeps Overweight rating on Monte Rosa Therapeutics, cuts target to $25